What is Inscripta?
Inscripta is at the forefront of developing the world's first benchtop platform designed for scalable digital genome engineering. Their sophisticated CRISPR-based system integrates an instrument, specialized consumables, intuitive software, and advanced assays. This comprehensive solution provides a fully automated workflow, enabling massively parallel and trackable editing of single cells at an unprecedented scale. Established in 2015 and headquartered in Boulder, Colorado, Inscripta is poised to transform how scientists approach genetic modification and analysis, offering a powerful tool for discovery and innovation in life sciences.
How much funding has Inscripta raised?
Inscripta has raised a total of $417.5M across 6 funding rounds:
Series A
$6M
Series B
$23M
Series C
$55.5M
Series D
$125M
Unspecified
$58M
Series E
$150M
Series A (2016): $6M, investors not publicly disclosed
Series B (2017): $23M led by Spruce/MLS, Paladin Capital Group, Venrock Healthcare Partners, NanoDimension, and Foresite Capital
Series C (2018): $55.5M supported by Venrock, Mérieux Développement, and Paladin Capital Group
Series D (2019): $125M featuring Oak HC/FT, Mérieux Développement, MLS Capital, Paladin Capital Group, NanoDimension, JS Capital Management LLC, Foresite, and Venrock
Unspecified (2020): $58M, investors not publicly disclosed
Series E (2021): $150M with participation from T. Rowe Price and Fidelity Management Corporation
Key Investors in Inscripta
T. Rowe Price
T. Rowe Price is a prominent investment management firm founded in 1937, offering services to a diverse clientele including individuals and institutional investors. The firm manages equity and fixed income mutual funds, investing across global public equity and fixed income markets. Headquartered in Baltimore, Maryland, T. Rowe Price is known for its deep research capabilities and long-term investment strategies.
Paladin Capital Group
Paladin Capital Group is a global multi-stage investment firm that specializes in venture capital and growth financing. They focus on identifying, supporting, and scaling companies across various sectors and development stages, leveraging deep sector expertise and operational acumen to accelerate growth and create enterprise value.
Venrock Healthcare Partners
Venrock, established in 1969, is a venture capital firm recognized for its entrepreneurial support and strategic guidance. With a strong track record in backing technology and healthcare ventures, Venrock partners with founders to build innovative, high-growth companies, offering deep industry expertise to help startups scale successfully.
What's next for Inscripta?
With the recent infusion of $150M in a major strategic investment, Inscripta is well-positioned to accelerate its growth trajectory. This capital injection is expected to fuel further development of its innovative genome engineering platform, enhance its go-to-market strategies, and expand its global presence. The company's focus on providing a scalable, automated solution for single-cell editing suggests a strategic push towards enabling broader adoption of advanced genomic tools across research institutions and biotechnology companies. Future endeavors will likely involve expanding assay capabilities, refining the instrument's performance, and forging strategic partnerships to drive the application of its technology in areas such as drug discovery, synthetic biology, and diagnostics.
See full Inscripta company page
